<DOC>
	<DOCNO>NCT00944905</DOCNO>
	<brief_summary>The purpose study determine MDX-1203 safe treatment renal cell carcinoma non-hodgkin 's lymphoma .</brief_summary>
	<brief_title>Study MDX-1203 Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma ( ccRCC ) Relapsed/Refractory B-Cell Non-Hodgkin 's Lymphoma ( B-NHL )</brief_title>
	<detailed_description>Multicenter , open-label , dose-escalation , multidose study MDX-1203 , fully human monoclonal antibody drug conjugate target CD70 transmembrane cell-surface protein highly express ccRCC B-NHL . MDX-1203 compose human anti-CD70 monoclonal antibody covalently link prodrug form cytotoxic deoxyribonucleic acid ( DNA ) minor-groove binding agent ( MGBA ) . The study consist 3 period : Screening ( 28 day ) , Treatment ( 17 cycle 2 year ) , Follow-up ( 6 month ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 Criteria specific tumor type : For Clear cell renal cell carcinoma ( ccRCC ) : advanced recurrent disease . Must fail least 1 prior systemic therapy For Bcell nonHodgkin 's lymphoma ( BNHL ) : Must fail least 1 prior systemic therapy Measurable disease criterion tumor type : For ccRCC : At least 1 unidimensional measurable lesion For BNHL : At least 1 bidimensionally measurable lesion Prior therapy advanced/recurrent ccRCC relapsed/refractory BNHL become intolerant systemic therapy Provide archive fresh tumor tissue CD70 status . Subjects must CD70+ Provision fresh tissue ( pretreatment ontreatment ) exploratory analysis mandatory least 5 maximum 10 BNHL subject Prior therapy antiCD70 antibody History severe hypersensitivity reaction monoclonal antibody Active untreated central nervous system lymphoma Active infection ( viral , bacterial , fungal ) Evidence bleed diathesis coagulopathy Active autoimmune disease require immunosuppressive therapy Known current drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>